Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.12.14

Sai Life Sciences Sustainability Report 2019-20

Sai Life Sciences releases its first Sustainability Report

• Developed as per the Global Reporting Initiative (GRI) standards
• Highlights the various sustainable choices embraced by the company in steering its journey on a sustainable path

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO/ CDMO), today announced the release of its first Sustainability Report as per the Global Reporting Initiative (GRI) standards. The report sheds light on the company’s progress during 2019-20 across the three pillars of sustainability i.e. economic, environment and social.

Making the announcement, Krishna Kanumuri, CEO & Managing Director said, “I am delighted to present our inaugural, 2019-2020 Sustainability Report. It reflects our deep commitment towards sustainability, in our pursuit of bringing new medicines to life. It also is a reaffirmation of our promise to Make it better together with all stakeholders, which functions as a key driver in continuously refining our sustainability practices and achieving business growth responsibly.”

The report highlights the company’s progress on all issues that are critical for its business and stakeholders. It details the various initiatives driving the company’s progress towards its stated sustainable development goals. During the year, Sai Life Sciences surpassed its goals for the responsible disposal of hazardous waste and its community outreach programs. It also is steadily progressing towards utilizing renewable power to meet its energy needs. It instituted the ‘Green Chemistry Awards’ to celebrate and recognize teams that demonstrate discernible improvements over established processes. The full report can be viewed here.

Speaking on the occasion, Sreekrishna Chopperla, Vice President & Head – Corporate Health, Safety & Environment said, “Over time, we have been able to inculcate in our employees an innate mindset towards sustainability. This enables our progress towards the sustainability development goals each day. We will continue to follow this path as we expand and grow, keeping sustainable development at the core.”

The release of the 2020 Sustainability Report caps a highly productive year for Sai Life Sciences from a sustainability perspective. Some of the highlights:

• Became the first India-headquartered company to join the PSCI membership.
• Received the ISO 14001:2015 and ISO 45001:2018 certifications for its R&D facility, manufacturing site and corporate office.
• Joined ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an ‘Associate Member’.
• Won the prestigious 21st National Award for Excellence in Energy Management 2020 by CII - Sohrabji Godrej Green Business Centre
• Received 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry (CII) South awards 2019.

Further, through its proactive response to the COVID-19 pandemic, the company ensured minimal impact on its stakeholders and business operations by safeguarding workforce, ensuring business continuity with its supplier and customers, and supporting the community.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more